**Additional file 1: Table S1**. Extracranial radiation prior to crizotinib

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Sex/Age | RT Site  | Symptom | Technique | Intention#  | Efficacy  | Severe Toxicity  |
| Case1 | M/41 | Thorax  | Obstructive pneumonitis | IMRT | Palliative | Symptomrelief  | None  |
| Case2 | M/41 | Bone | Pain  | SBRT | Palliative | Pain relief | None  |
| Case3 | F/49 | Bone | Pain | SBRT | Palliative | Pain relief  | None |
| Case4 | M/49 | Thorax  | Not specific  | IMRT | Ablative  | Tumor reduction | None |
| Case5 | M/45 | Thorax | Not specific  | SBRT | Ablative | Tumor reduction  | None |
| Case6 | M/57 | Bone  | Pain  | SBRT | Palliative  | Pain relief | None |
| Case7 | M/53 | Thorax  | Not specific  | IMRT | Ablative  | Tumor reduction  | None |
| Case8 | M/39 | Thorax  | Not specific  | IMRT | Ablative | Tumor reduction  | Febrileneutropenia |
| Case9 | F/38 | Adrenal gland, Thorax | Not specific  | SBRT | Ablative  | Tumor reduction  | Skin injury |
| Case10 | M/53 | Thorax  | Esophageal obstruction | IMRT | Palliative  | Symptomrelief  | None |
| Case11 | F/58 | Thorax  | SVCS | IMRT | Palliative  | Symptomrelief | None |
| Case12 | F/53 | Bone  | Pain  | IMRT | Palliative  | Pain relief | None |
| Case13 | F/48 | Bone | Pain, Pathological fracture  | IMRT | Palliative  | Pain relief  | None |
| Case14\* | F/50 | Thorax  | Not specific  | IMRT | Palliative  | Tumor reduction | Radiation pneumonitis |
| Case15 | M/52 | Thorax | Not specific  | IMRT | Ablative  | Stable disease | None |

RT: radiotherapy, IMRT: intensity-modulated radiation therapy, SBRT: stereotactic body radiation therapy, SVCS: superior vena cava syndrome

Not specific: patients did not have specific symptoms that warranted immediate palliative radiation

\*: Ablative thoracic radiation was planed for this patient and ended up as palliative radiation due to the development of grade 3 radiation pneumonitis

#: Thoracic radiation was considered ablative with a biologic effective dose (BED)≥60 Gy10 for IMRT and with a BED ≥100 Gy10 for SBRT, adapted from previous studies[[1](#_ENREF_1),[2](#_ENREF_2)]

**Reference**:

[1] Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clinical lung cancer 2014;15:346-355.

[2] Gomez DR, Blumenschein GR, Jr., Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. The Lancet. Oncology 2016;17:1672-1682.